 |
PDBsum entry 1epw
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.24.69
- bontoxilysin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Limited hydrolysis of proteins of the neuroexocytosis apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on small molecule substrates.
|
 |
 |
 |
 |
 |
Cofactor:
|
 |
Zn(2+)
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nat Struct Biol
7:693-699
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.
|
|
S.Swaminathan,
S.Eswaramoorthy.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Clostridium botulinum neurotoxins are among the most potent toxins to humans.
The crystal structures of intact C. botulinum neurotoxin type B (BoNT/B) and its
complex with sialyllactose, determined at 1. 8 and 2.6 A resolution,
respectively, provide insight into its catalytic and binding sites. The position
of the belt region in BoNT/B is different from that in BoNT/A; this observation
presents interesting possibilities for designing specific inhibitors that could
be used to block the activity of this neurotoxin. The structures of BoNT/B and
its complex with sialyllactose provide a detailed description of the active site
and a model for interactions between the toxin and its cell surface receptor.
The latter may provide valuable information for recombinant vaccine development.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. The active and binding sites of BoNT/B. a, Stereo
view of the active site environment. Zinc and bonds to its
coordinating residues are shown in orange. Residues in the first
shell around the zinc (the immediate surroundings) are shown as
ball and stick models, while residues in the second shell and
water molecules are shown as ball and stick models with their
van der Waals surfaces as dotted surfaces. Hydrogen bonds are
shown as thin blue lines. b, Stereo view of sialyllactose and
the residues interacting with it. Residues from a symmetry
related molecule are shown in blue. Potential hydrogen bond
contacts are shown as dashed lines.
|
 |
Figure 6.
Figure 6. Sigma weighted 2F[o] - F[c] maps. a, A
representative section of the 2F[o] - F[c] map of intact BoNT/B
structure contoured at 1.2 .
All reflections up to 1.8 Å resolution were included in the map
calculations. b, 2F[o] - F[c] map showing density around
sialyllactose contoured at 1.0 in
the crystal structure of BoNT/B in complex with sialyllactose.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Biol
(2000,
7,
693-699)
copyright 2000.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
G.Masuyer,
M.Beard,
V.A.Cadd,
J.A.Chaddock,
and
K.R.Acharya
(2011).
Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B.
|
| |
J Struct Biol,
174,
52-57.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
I.Azimi,
J.W.Wong,
and
P.J.Hogg
(2011).
Control of mature protein function by allosteric disulfide bonds.
|
| |
Antioxid Redox Signal,
14,
113-126.
|
 |
|
|
|
|
 |
B.Clapp,
S.Golden,
M.Maddaloni,
H.F.Staats,
and
D.W.Pascual
(2010).
Adenovirus F protein as a delivery vehicle for botulinum B.
|
| |
BMC Immunol,
11,
36.
|
 |
|
|
|
|
 |
B.Lai,
R.Agarwal,
L.D.Nelson,
S.Swaminathan,
and
E.London
(2010).
Low pH-induced pore formation by the T domain of botulinum toxin type A is dependent upon NaCl concentration.
|
| |
J Membr Biol,
236,
191-201.
|
 |
|
|
|
|
 |
J.Strotmeier,
K.Lee,
A.K.Völker,
S.Mahrhold,
Y.Zong,
J.Zeiser,
J.Zhou,
A.Pich,
H.Bigalke,
T.Binz,
A.Rummel,
and
R.Jin
(2010).
Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner.
|
| |
Biochem J,
431,
207-216.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.C.Scotcher,
L.W.Cheng,
and
L.H.Stanker
(2010).
Detection of botulinum neurotoxin serotype B at sub mouse LD(50) levels by a sandwich immunoassay and its application to toxin detection in milk.
|
| |
PLoS One,
5,
e11047.
|
 |
|
|
|
|
 |
M.Montal
(2010).
Botulinum neurotoxin: a marvel of protein design.
|
| |
Annu Rev Biochem,
79,
591-617.
|
 |
|
|
|
|
 |
N.Gul,
L.A.Smith,
and
S.A.Ahmed
(2010).
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
|
| |
PLoS One,
5,
e12872.
|
 |
|
|
|
|
 |
P.Stenmark,
M.Dong,
J.Dupuy,
E.R.Chapman,
and
R.C.Stevens
(2010).
Crystal structure of the botulinum neurotoxin type G binding domain: insight into cell surface binding.
|
| |
J Mol Biol,
397,
1287-1297.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Fujinaga
(2010).
Interaction of botulinum toxin with the epithelial barrier.
|
| |
J Biomed Biotechnol,
2010,
974943.
|
 |
|
|
|
|
 |
A.Fischer,
Y.Nakai,
L.M.Eubanks,
C.M.Clancy,
W.H.Tepp,
S.Pellett,
T.J.Dickerson,
E.A.Johnson,
K.D.Janda,
and
M.Montal
(2009).
Bimodal modulation of the botulinum neurotoxin protein-conducting channel.
|
| |
Proc Natl Acad Sci U S A,
106,
1330-1335.
|
 |
|
|
|
|
 |
A.Rummel,
K.Häfner,
S.Mahrhold,
N.Darashchonak,
M.Holt,
R.Jahn,
S.Beermann,
T.Karnath,
H.Bigalke,
and
T.Binz
(2009).
Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
|
| |
J Neurochem,
110,
1942-1954.
|
 |
|
|
|
|
 |
C.Chen,
Z.Fu,
J.J.Kim,
J.T.Barbieri,
and
M.R.Baldwin
(2009).
Gangliosides as high affinity receptors for tetanus neurotoxin.
|
| |
J Biol Chem,
284,
26569-26577.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Shone,
H.Agostini,
J.Clancy,
M.Gu,
H.H.Yang,
Y.Chu,
V.Johnson,
M.Taal,
J.McGlashan,
J.Brehm,
and
X.Tong
(2009).
Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.
|
| |
Infect Immun,
77,
2795-2801.
|
 |
|
|
|
|
 |
K.Umeda,
Y.Seto,
T.Kohda,
M.Mukamoto,
and
S.Kozaki
(2009).
Genetic characterization of Clostridium botulinum associated with type B infant botulism in Japan.
|
| |
J Clin Microbiol,
47,
2720-2728.
|
 |
|
|
|
|
 |
M.C.Scotcher,
E.A.Johnson,
and
L.H.Stanker
(2009).
Characterization of the epitope region of F1-2 and F1-5, two monoclonal antibodies to Botulinum neurotoxin type A.
|
| |
Hybridoma (Larchmt),
28,
315-325.
|
 |
|
|
|
|
 |
M.C.Scotcher,
J.A.McGarvey,
E.A.Johnson,
and
L.H.Stanker
(2009).
Epitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain).
|
| |
PLoS ONE,
4,
e4924.
|
 |
|
|
|
|
 |
M.Montal
(2009).
Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel.
|
| |
Toxicon,
54,
565-569.
|
 |
|
|
|
|
 |
M.R.Popoff,
and
P.Bouvet
(2009).
Clostridial toxins.
|
| |
Future Microbiol,
4,
1021-1064.
|
 |
|
|
|
|
 |
A.C.Doxey,
M.D.Lynch,
K.M.Müller,
E.M.Meiering,
and
B.J.McConkey
(2008).
Insights into the evolutionary origins of clostridial neurotoxins from analysis of the Clostridium botulinum strain A neurotoxin gene cluster.
|
| |
BMC Evol Biol,
8,
316.
|
 |
|
|
|
|
 |
A.Fischer,
C.Garcia-Rodriguez,
I.Geren,
J.Lou,
J.D.Marks,
T.Nakagawa,
and
M.Montal
(2008).
Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy.
|
| |
J Biol Chem,
283,
3997-4003.
|
 |
|
|
|
|
 |
A.Fischer,
D.J.Mushrush,
D.B.Lacy,
and
M.Montal
(2008).
Botulinum neurotoxin devoid of receptor binding domain translocates active protease.
|
| |
PLoS Pathog,
4,
e1000245.
|
 |
|
|
|
|
 |
A.Imberty,
and
A.Varrot
(2008).
Microbial recognition of human cell surface glycoconjugates.
|
| |
Curr Opin Struct Biol,
18,
567-576.
|
 |
|
|
|
|
 |
B.R.Eapen
(2008).
Molecular biology of botulinum neurotoxin serotype A: a cosmetic perspective.
|
| |
J Cosmet Dermatol,
7,
221-225.
|
 |
|
|
|
|
 |
D.J.Chiao,
J.J.Wey,
R.H.Shyu,
and
S.S.Tang
(2008).
Monoclonal antibody-based lateral flow assay for detection of botulinum neurotoxin type A.
|
| |
Hybridoma (Larchmt),
27,
31-35.
|
 |
|
|
|
|
 |
D.J.Chiao,
J.J.Wey,
and
S.S.Tang
(2008).
Monoclonal antibody-based enzyme immunoassay for detection of botulinum neurotoxin type A.
|
| |
Hybridoma (Larchmt),
27,
43-47.
|
 |
|
|
|
|
 |
D.Kumaran,
R.Rawat,
M.L.Ludivico,
S.A.Ahmed,
and
S.Swaminathan
(2008).
Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A.
|
| |
J Biol Chem,
283,
18883-18891.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.Kumaran,
R.Rawat,
S.A.Ahmed,
and
S.Swaminathan
(2008).
Substrate binding mode and its implication on drug design for botulinum neurotoxin A.
|
| |
PLoS Pathog,
4,
e1000165.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Galloux,
H.Vitrac,
C.Montagner,
S.Raffestin,
M.R.Popoff,
A.Chenal,
V.Forge,
and
D.Gillet
(2008).
Membrane Interaction of Botulinum Neurotoxin A Translocation (T) Domain: THE BELT REGION IS A REGULATORY LOOP FOR MEMBRANE INTERACTION.
|
| |
J Biol Chem,
283,
27668-27676.
|
 |
|
|
|
|
 |
P.Stenmark,
J.Dupuy,
A.Imamura,
M.Kiso,
and
R.C.Stevens
(2008).
Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction.
|
| |
PLoS Pathog,
4,
e1000129.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.A.Ahmed,
M.A.Olson,
M.L.Ludivico,
J.Gilsdorf,
and
L.A.Smith
(2008).
Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
|
| |
Protein J,
27,
151-162.
|
 |
|
|
|
|
 |
A.Fischer,
and
M.Montal
(2007).
Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes.
|
| |
Proc Natl Acad Sci U S A,
104,
10447-10452.
|
 |
|
|
|
|
 |
A.Fischer,
and
M.Montal
(2007).
Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes.
|
| |
J Biol Chem,
282,
29604-29611.
|
 |
|
|
|
|
 |
A.Rummel,
T.Eichner,
T.Weil,
T.Karnath,
A.Gutcaits,
S.Mahrhold,
K.Sandhoff,
R.L.Proia,
K.R.Acharya,
H.Bigalke,
and
T.Binz
(2007).
Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept.
|
| |
Proc Natl Acad Sci U S A,
104,
359-364.
|
 |
|
|
|
|
 |
A.T.Brunger,
M.A.Breidenbach,
R.Jin,
A.Fischer,
J.S.Santos,
and
M.Montal
(2007).
Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain.
|
| |
PLoS Pathog,
3,
1191-1194.
|
 |
|
|
|
|
 |
E.Ravichandran,
F.H.Al-Saleem,
D.M.Ancharski,
M.D.Elias,
A.K.Singh,
M.Shamim,
Y.Gong,
and
L.L.Simpson
(2007).
Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.
|
| |
Infect Immun,
75,
3043-3054.
|
 |
|
|
|
|
 |
K.Hasegawa,
T.Watanabe,
T.Suzuki,
A.Yamano,
T.Oikawa,
Y.Sato,
H.Kouguchi,
T.Yoneyama,
K.Niwa,
T.Ikeda,
and
T.Ohyama
(2007).
A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms.
|
| |
J Biol Chem,
282,
24777-24783.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.R.Baldwin,
J.J.Kim,
and
J.T.Barbieri
(2007).
Botulinum neurotoxin B-host receptor recognition: it takes two receptors to tango.
|
| |
Nat Struct Mol Biol,
14,
9.
|
 |
|
|
|
|
 |
N.R.Silvaggi,
G.E.Boldt,
M.S.Hixon,
J.P.Kennedy,
S.Tzipori,
K.D.Janda,
and
K.N.Allen
(2007).
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.
|
| |
Chem Biol,
14,
533-542.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Ansiaux,
and
B.Gallez
(2007).
Use of botulinum toxins in cancer therapy.
|
| |
Expert Opin Investig Drugs,
16,
209-218.
|
 |
|
|
|
|
 |
R.Levy,
C.M.Forsyth,
S.L.LaPorte,
I.N.Geren,
L.A.Smith,
and
J.D.Marks
(2007).
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
|
| |
J Mol Biol,
365,
196-210.
|
 |
|
|
|
|
 |
S.Chen,
J.J.Kim,
and
J.T.Barbieri
(2007).
Mechanism of substrate recognition by botulinum neurotoxin serotype A.
|
| |
J Biol Chem,
282,
9621-9627.
|
 |
|
|
|
|
 |
T.Kohda,
H.Ihara,
Y.Seto,
H.Tsutsuki,
M.Mukamoto,
and
S.Kozaki
(2007).
Differential contribution of the residues in C-terminal half of the heavy chain of botulinum neurotoxin type B to its binding to the ganglioside GT1b and the synaptotagmin 2/GT1b complex.
|
| |
Microb Pathog,
42,
72-79.
|
 |
|
|
|
|
 |
X.Chen,
and
Y.Deng
(2007).
Long-time molecular dynamics simulations of botulinum biotoxin type-A at different pH values and temperatures.
|
| |
J Mol Model,
13,
559-572.
|
 |
|
|
|
|
 |
A.Fisher,
and
M.Montal
(2006).
Characterization of Clostridial botulinum neurotoxin channels in neuroblastoma cells.
|
| |
Neurotox Res,
9,
93.
|
 |
|
|
|
|
 |
B.R.DasGupta
(2006).
Botulinum neurotoxins: perspective on their existence and as polyproteins harboring viral proteases.
|
| |
J Gen Appl Microbiol,
52,
1-8.
|
 |
|
|
|
|
 |
B.R.Singh
(2006).
Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.
|
| |
Neurotox Res,
9,
73-92.
|
 |
|
|
|
|
 |
F.Cai,
C.B.Adrion,
and
J.E.Keller
(2006).
Comparison of extracellular and intracellular potency of botulinum neurotoxins.
|
| |
Infect Immun,
74,
5617-5624.
|
 |
|
|
|
|
 |
K.A.Foster,
H.Bigalke,
and
K.R.Aoki
(2006).
Botulinum neurotoxin - from laboratory to bedside.
|
| |
Neurotox Res,
9,
133-140.
|
 |
|
|
|
|
 |
M.C.Conway,
R.M.Whittal,
M.A.Baldwin,
A.L.Burlingame,
and
R.Balhorn
(2006).
Electrospray mass spectrometry of NeuAc oligomers associated with the C fragment of the tetanus toxin.
|
| |
J Am Soc Mass Spectrom,
17,
967-976.
|
 |
|
|
|
|
 |
M.F.Li,
and
Y.L.Shi
(2006).
Toosendanin interferes with pore formation of botulinum toxin type A in PC12 cell membrane.
|
| |
Acta Pharmacol Sin,
27,
66-70.
|
 |
|
|
|
|
 |
O.Rossetto,
L.Morbiato,
P.Caccin,
M.Rigoni,
and
C.Montecucco
(2006).
Presynaptic enzymatic neurotoxins.
|
| |
J Neurochem,
97,
1534-1545.
|
 |
|
|
|
|
 |
B.R.Dasgupta,
B.S.Antharavally,
W.Tepp,
and
M.L.Evenson
(2005).
Botulinum neurotoxin types A, B, and E: fragmentations by autoproteolysis and other mechanisms including by O-phenanthroline-dithiothreitol, and association of the dinucleotides NAD(+)/NADH with the heavy chain of the three neurotoxins.
|
| |
Protein J,
24,
337-368.
|
 |
|
|
|
|
 |
C.Anne,
S.Turcaud,
A.G.Blommaert,
F.Darchen,
E.A.Johnson,
and
B.P.Roques
(2005).
Partial protection against Botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity.
|
| |
Chembiochem,
6,
1375-1380.
|
 |
|
|
|
|
 |
K.A.Foster
(2005).
A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics.
|
| |
Drug Discov Today,
10,
563-569.
|
 |
|
|
|
|
 |
M.A.Breidenbach,
and
A.T.Brunger
(2005).
New insights into clostridial neurotoxin-SNARE interactions.
|
| |
Trends Mol Med,
11,
377-381.
|
 |
|
|
|
|
 |
R.Kukreja,
and
B.Singh
(2005).
Biologically active novel conformational state of botulinum, the most poisonous poison.
|
| |
J Biol Chem,
280,
39346-39352.
|
 |
|
|
|
|
 |
S.Jayaraman,
S.Eswaramoorthy,
D.Kumaran,
and
S.Swaminathan
(2005).
Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin.
|
| |
Proteins,
61,
288-295.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.J.Smith,
J.Lou,
I.N.Geren,
C.M.Forsyth,
R.Tsai,
S.L.Laporte,
W.H.Tepp,
M.Bradshaw,
E.A.Johnson,
L.A.Smith,
and
J.D.Marks
(2005).
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
|
| |
Infect Immun,
73,
5450-5457.
|
 |
|
|
|
|
 |
A.Rummel,
S.Mahrhold,
H.Bigalke,
and
T.Binz
(2004).
The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction.
|
| |
Mol Microbiol,
51,
631-643.
|
 |
|
|
|
|
 |
A.Rummel,
T.Karnath,
T.Henke,
H.Bigalke,
and
T.Binz
(2004).
Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G.
|
| |
J Biol Chem,
279,
30865-30870.
|
 |
|
|
|
|
 |
C.Montecucco,
O.Rossetto,
and
G.Schiavo
(2004).
Presynaptic receptor arrays for clostridial neurotoxins.
|
| |
Trends Microbiol,
12,
442-446.
|
 |
|
|
|
|
 |
C.Sukonpan,
T.Oost,
M.Goodnough,
W.Tepp,
E.A.Johnson,
and
D.H.Rich
(2004).
Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease.
|
| |
J Pept Res,
63,
181-193.
|
 |
|
|
|
|
 |
D.D.Whelchel,
T.M.Brehmer,
P.M.Brooks,
N.Darragh,
and
J.A.Coffield
(2004).
Molecular targets of botulinum toxin at the mammalian neuromuscular junction.
|
| |
Mov Disord,
19,
S7.
|
 |
|
|
|
|
 |
E.Fernández-Salas,
H.Ho,
P.Garay,
L.E.Steward,
and
K.R.Aoki
(2004).
Is the light chain subcellular localization an important factor in botulinum toxin duration of action?
|
| |
Mov Disord,
19,
S23-S34.
|
 |
|
|
|
|
 |
E.Fernández-Salas,
L.E.Steward,
H.Ho,
P.E.Garay,
S.W.Sun,
M.A.Gilmore,
J.V.Ordas,
J.Wang,
J.Francis,
and
K.R.Aoki
(2004).
Plasma membrane localization signals in the light chain of botulinum neurotoxin.
|
| |
Proc Natl Acad Sci U S A,
101,
3208-3213.
|
 |
|
|
|
|
 |
F.J.Lebeda
(2004).
BotDB: A database resource for the clostridial neurotoxins.
|
| |
Mov Disord,
19,
S35-S41.
|
 |
|
|
|
|
 |
K.A.Foster
(2004).
The analgesic potential of clostridial neurotoxin derivatives.
|
| |
Expert Opin Investig Drugs,
13,
1437-1443.
|
 |
|
|
|
|
 |
L.L.Simpson
(2004).
Identification of the major steps in botulinum toxin action.
|
| |
Annu Rev Pharmacol Toxicol,
44,
167-193.
|
 |
|
|
|
|
 |
N.Gul,
S.A.Ahmed,
and
L.A.Smith
(2004).
Inhibition of the protease activity of the light chain of type A botulinum neurotoxin by aqueous extract from stinging nettle (Urtica dioica) leaf.
|
| |
Basic Clin Pharmacol Toxicol,
95,
215-219.
|
 |
|
|
|
|
 |
S.Swaminathan,
S.Eswaramoorthy,
and
D.Kumaran
(2004).
Structure and enzymatic activity of botulinum neurotoxins.
|
| |
Mov Disord,
19,
S17-S22.
|
 |
|
|
|
|
 |
E.A.Neale
(2003).
Moving across membranes.
|
| |
Nat Struct Biol,
10,
2-3.
|
 |
|
|
|
|
 |
G.Lalli,
S.Bohnert,
K.Deinhardt,
C.Verastegui,
and
G.Schiavo
(2003).
The journey of tetanus and botulinum neurotoxins in neurons.
|
| |
Trends Microbiol,
11,
431-437.
|
 |
|
|
|
|
 |
H.Bruggemann,
S.Baumer,
W.F.Fricke,
A.Wiezer,
H.Liesegang,
I.Decker,
C.Herzberg,
R.Martinez-Arias,
R.Merkl,
A.Henne,
and
G.Gottschalk
(2003).
The genome sequence of Clostridium tetani, the causative agent of tetanus disease.
|
| |
Proc Natl Acad Sci U S A,
100,
1316-1321.
|
 |
|
|
|
|
 |
L.K.Koriazova,
and
M.Montal
(2003).
Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.
|
| |
Nat Struct Biol,
10,
13-18.
|
 |
|
|
|
|
 |
M.Maresca,
R.Mahfoud,
N.Garmy,
D.P.Kotler,
J.Fantini,
and
F.Clayton
(2003).
The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line.
|
| |
J Biomed Sci,
10,
156-166.
|
 |
|
|
|
|
 |
P.G.Foran,
B.Davletov,
and
F.A.Meunier
(2003).
Getting muscles moving again after botulinum toxin: novel therapeutic challenges.
|
| |
Trends Mol Med,
9,
291-299.
|
 |
|
|
|
|
 |
S.A.Ahmed,
P.McPhie,
and
L.A.Smith
(2003).
Autocatalytically fragmented light chain of botulinum a neurotoxin is enzymatically active.
|
| |
Biochemistry,
42,
12539-12549.
|
 |
|
|
|
|
 |
T.Oost,
C.Sukonpan,
M.Brewer,
M.Goodnough,
W.Tepp,
E.A.Johnson,
and
D.H.Rich
(2003).
Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease.
|
| |
Biopolymers,
71,
602-619.
|
 |
|
|
|
|
 |
K.Turton,
J.A.Chaddock,
and
K.R.Acharya
(2002).
Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.
|
| |
Trends Biochem Sci,
27,
552-558.
|
 |
|
|
|
|
 |
S.Eswaramoorthy,
D.Kumaran,
and
S.Swaminathan
(2002).
A novel mechanism for Clostridium botulinum neurotoxin inhibition.
|
| |
Biochemistry,
41,
9795-9802.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.P.Mullaney,
M.G.Pallavicini,
and
J.D.Marks
(2001).
Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
|
| |
Infect Immun,
69,
6511-6514.
|
 |
|
|
|
|
 |
C.Blanes-Mira,
C.Ibañez,
G.Fernández-Ballester,
R.Planells-Cases,
E.Pérez-Payá,
and
A.Ferrer-Montiel
(2001).
Thermal stabilization of the catalytic domain of botulinum neurotoxin E by phosphorylation of a single tyrosine residue.
|
| |
Biochemistry,
40,
2234-2242.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |